Skip to main content

Advertisement

Table 2 Multivariate analysis of factors affecting intracranial PFS and OS in NSCLC patients with brain metastasis

From: The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases

Factors Intracranial PFS OS
N HR 95%CI P HR 95%CI P
With RPA and GPA in the model
 Smoking 108/130 1.42 1.07–1.88 0.02 1.48 1.04–2.10 0.03
 Primary disease controlled 31/207 0.54 0.36–0.81 0.003 0.36 0.23–0.57 <0.001
 RTOG RPA class 50/188 1.81 1.17–2.79 0.008 1.99 1.15–3.45 0.01
 Therapeutic schedule 109/129 0.66 0.50–0.88 0.004    
 RTOG GPA grade 143/95     0.58 0.36–0.93 0.02
Without RPA and GPA in the model
 Smoking 108/130 1.39 1.04–1.84 0.02 1.48 1.05–2.10 0.03
 Number of BM 65/173 1.47 1.08–2.00 0.02 1.58 1.08–2.33 0.02
 Primary disease controlled 31/207 0.57 0.38–0.86 0.007 0.38 0.24–0.60 <0.001
 Therapeutic schedule 109/129 0.66 0.50–0.88 0.004    
 EGOC PS 188/50     1.76 1.21–2.57 0.003
  1. Abbreviations: RPA recursive partitioning analysis, GPA graded prognostic assessment, BM brain metastasis, Eastern Cooperative Oncology Group performance status ECOG PS, the Radiation Therapy Oncology Group RTOG, confidence interval CI, hazard ratio HR